Total Payments
$471,187
2024 Payments
$74,572
Companies
37
Transactions
1,108
Medicare Patients
1,282
Medicare Billing
$157,903
Payment Breakdown by Category
Other$357,547 (75.9%)
Consulting$61,468 (13.0%)
Travel$30,228 (6.4%)
Food & Beverage$21,706 (4.6%)
Education$238.35 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $309,237 | 143 | 65.6% |
| Consulting Fee | $61,468 | 70 | 13.0% |
| Honoraria | $38,110 | 15 | 8.1% |
| Travel and Lodging | $30,228 | 134 | 6.4% |
| Food and Beverage | $21,706 | 733 | 4.6% |
| Compensation for serving as faculty or as a speaker for a medical education program | $10,200 | 5 | 2.2% |
| Education | $238.35 | 8 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $121,558 | 167 | $0 (2024) |
| Abbott Laboratories | $76,508 | 282 | $0 (2024) |
| PFIZER INC. | $51,561 | 30 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $44,929 | 309 | $0 (2024) |
| Lexicon Pharmaceuticals, Inc. | $33,465 | 45 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $32,814 | 59 | $0 (2024) |
| Alnylam Pharmaceuticals Inc. | $32,791 | 40 | $0 (2024) |
| SCPHARMACEUTICALS INC. | $26,540 | 26 | $0 (2024) |
| Relypsa, Inc. | $13,301 | 17 | $0 (2020) |
| Vifor Pharma, Inc. | $7,865 | 6 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $74,572 | 160 | Lexicon Pharmaceuticals, Inc. ($33,386) |
| 2023 | $75,511 | 163 | SCPHARMACEUTICALS INC. ($22,059) |
| 2022 | $38,248 | 116 | Abbott Laboratories ($21,563) |
| 2021 | $68,146 | 144 | AstraZeneca Pharmaceuticals LP ($18,834) |
| 2020 | $54,413 | 112 | PFIZER INC. ($13,358) |
| 2019 | $57,123 | 118 | Novartis Pharmaceuticals Corporation ($36,348) |
| 2018 | $70,845 | 194 | Novartis Pharmaceuticals Corporation ($55,638) |
| 2017 | $32,328 | 101 | Novartis Pharmaceuticals Corporation ($25,794) |
All Payment Transactions
1,108 individual payment records from CMS Open Payments — Page 1 of 45
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | PFIZER INC. | VYNDAMAX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,400.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/19/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $35.93 | General |
| Category: Cardiology | ||||||
| 12/18/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $24.52 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/16/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $23.20 | General |
| Category: Genetic Disease | ||||||
| 12/12/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $22.20 | General |
| Category: Cardiology | ||||||
| 12/04/2024 | iRhythm Technologies, Inc. | ZIO XT Patch (Device), Zio monitor | Food and Beverage | In-kind items and services | $26.22 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/02/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,570.00 | General |
| Category: Genetic Disease | ||||||
| 12/02/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Travel and Lodging | Cash or cash equivalent | $93.90 | General |
| Category: Genetic Disease | ||||||
| 11/21/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $34.56 | General |
| Category: Cardiology | ||||||
| 11/21/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $2.34 | General |
| Category: Cardiology | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $22.95 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/15/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Travel and Lodging | Cash or cash equivalent | $94.34 | General |
| Category: Cardiology | ||||||
| 11/15/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Travel and Lodging | Cash or cash equivalent | $11.38 | General |
| Category: Cardiology | ||||||
| 11/13/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $28.35 | General |
| Category: Cardiology | ||||||
| 11/07/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Travel and Lodging | In-kind items and services | $498.98 | General |
| Category: Genetic Disease | ||||||
| 11/07/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Travel and Lodging | In-kind items and services | $335.47 | General |
| Category: Genetic Disease | ||||||
| 11/07/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Travel and Lodging | In-kind items and services | $334.64 | General |
| Category: Genetic Disease | ||||||
| 11/07/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $18.74 | General |
| 11/06/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $46.73 | General |
| Category: Genetic Disease | ||||||
| 10/28/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,520.00 | General |
| Category: Cardiology | ||||||
| 10/24/2024 | Abbott Laboratories | THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) | Food and Beverage | In-kind items and services | $10.54 | General |
| Category: Heart Failure | ||||||
| 10/23/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Cardiology | ||||||
| 10/22/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $33.37 | General |
| Category: Cardiology | ||||||
| 10/18/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,190.00 | General |
| Category: Genetic Disease | ||||||
| 10/15/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,380.00 | General |
| Category: Genetic Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 324 | 1,253 | $112,992 | $41,642 |
| 2022 | 9 | 247 | 1,015 | $78,824 | $32,470 |
| 2021 | 11 | 350 | 1,170 | $94,638 | $39,984 |
| 2020 | 12 | 361 | 1,206 | $99,704 | $43,808 |
Total Patients
1,282
Total Services
4,644
Medicare Billing
$157,903
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 93793 | Anticoagulant management of patient taking warfarin | Facility | 2023 | 29 | 852 | $16,904 | $6,999 | 41.4% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 19 | 39 | $20,456 | $6,417 | 31.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 65 | 84 | $24,545 | $5,895 | 24.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 42 | 87 | $10,143 | $5,391 | 53.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 39 | 57 | $9,585 | $5,220 | 54.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 23 | $7,530 | $3,125 | 41.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 25 | 26 | $8,011 | $2,703 | 33.7% |
| 93451 | Insertion of tube in right heart chambers for measurement | Facility | 2023 | 19 | 20 | $4,709 | $1,988 | 42.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 12 | 12 | $4,144 | $1,695 | 40.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 15 | 16 | $3,539 | $1,353 | 38.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 14 | 14 | $3,108 | $722.40 | 23.2% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 22 | 23 | $317.63 | $133.98 | 42.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 46 | 94 | $15,807 | $7,070 | 44.7% |
| 93793 | Anticoagulant management of patient taking warfarin | Facility | 2022 | 20 | 660 | $13,094 | $5,362 | 40.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 42 | 95 | $11,076 | $5,094 | 46.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 54 | 69 | $13,405 | $4,884 | 36.4% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 13 | 21 | $9,283 | $3,379 | 36.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 12 | $3,929 | $1,867 | 47.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 17 | 17 | $4,857 | $1,839 | 37.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 31 | 34 | $4,497 | $1,704 | 37.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 13 | 13 | $2,875 | $1,272 | 44.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 55 | 129 | $15,040 | $6,909 | 45.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 53 | 83 | $13,957 | $6,045 | 43.3% |
| 93793 | Anti-clotting management for patient taking warfarin | Facility | 2021 | 25 | 706 | $14,007 | $5,987 | 42.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 62 | 81 | $10,494 | $4,049 | 38.6% |
About Dr. Scott Feitell, D.O
Dr. Scott Feitell, D.O is a Internal Medicine healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/04/2010. The National Provider Identifier (NPI) number assigned to this provider is 1770815540.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Scott Feitell, D.O has received a total of $471,187 in payments from pharmaceutical and medical device companies, with $74,572 received in 2024. These payments were reported across 1,108 transactions from 37 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($309,237).
As a Medicare-enrolled provider, Feitell has provided services to 1,282 Medicare beneficiaries, totaling 4,644 services with total Medicare billing of $157,903. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Cardiovascular Disease, Hospitalist
- Location Rochester, NY
- Active Since 02/04/2010
- Last Updated 09/22/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1770815540
Products in Payments
- ENTRESTO (Drug) $121,477
- VYNDAQEL (Drug) $47,086
- Inpefa (Drug) $33,383
- FARXIGA (Drug) $32,736
- AMVUTTRA (Drug) $31,119
- FUROSCIX (Drug) $26,540
- UPTRAVI (Drug) $25,168
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) $23,877
- Veltassa (Drug) $21,165
- MITRACLIP (Device) $16,115
- HeartMate 3 Left Ventricular Assist Device (Device) $11,108
- CardioMEMS HF System (Device) $8,166
- HeartMate 3 Left Ventricular Dev (Device) $7,475
- TEGSEDI (Drug) $5,571
- OPTIMIZER (Device) $4,914
- OPSUMIT (Drug) $4,797
- ReDS system (Device) $4,782
- VYNDAMAX (Drug) $4,400
- Proclaim Family of SCS IPGs (Device) $3,271
- HeartMate Touch (Device) $3,106
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Rochester
Dr. Ben George, M.d, M.D
Internal Medicine — Payments: $729,795
Internal Medicine $729,795
John Kisiel, M.d, M.D
Internal Medicine — Payments: $550,377
Internal Medicine $550,377
Gregory Poland, M.d, M.D
Internal Medicine — Payments: $532,099
Internal Medicine $532,099
Christopher Ritchlin, Md, MD
Internal Medicine — Payments: $512,889
Internal Medicine $512,889
Prashant Kapoor, Md, MD
Internal Medicine — Payments: $403,295
Internal Medicine $403,295
Irina Bancos, M.d, M.D
Internal Medicine — Payments: $360,053
Internal Medicine $360,053